secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001104659-23-026995
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts
--------------------------------------------------------------------------------

- Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.
- IMCIVREE for BBS: >200 new scripts from >125 physicians, >100 reimbursement approvals since FDA approval June 2022.
- Acquired Xinvento B.V. for congenital hyperinsulinism; founder Claudine van der Sande joins as VP, Head of CHI Program.
- Initiated pivotal Phase 3 trial for setmelanotide in acquired hypothalamic obesity; patient screening underway.
- FY 2023 non-GAAP operating expense guidance $200M-$220M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/tm237866d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-026995

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer